FDA
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $23 at H.C. Wainwright
-
-
-
-
-
-
-
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
-
-
-
-
-
-
-
FDA aligns with Regenxbio on path to refile MPS II gene therapy BLA
-
-
-
-
-
-
-
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit — The Gross Law Firm
-
-
-
-
-
-
-
REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before April 14, 2026 to Discuss Your Rights – RGNX
-
-
-
-
-
-
-
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2026 in REGENXBIO Lawsuit - RGNX
-
-
-
-
-
-
-
REGENXBIO receives FDA rejection letter for gene therapy RGX-121
-
332,016 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

